A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors

Trial Profile

A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Prexasertib (Primary) ; Cetuximab; Cisplatin; Fluorouracil; Folinic acid; Granulocyte colony-stimulating factors; LY 3023414; Pemetrexed
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Mar 2017 Planned End Date changed from 1 Apr 2018 to 27 Apr 2019.
    • 08 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 27 Apr 2019.
    • 07 Jan 2016 Number of treatment arms changed from 3 to 5. Fluorouracil and LY3023414 drugs are added to the treatment. Primary end points are added accordingly as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top